Claim
In the phase 1 mRNA-1215 trial, antibody responses increased after the booster dose and remained elevated for at least one year.
a conjunction joins clauses that may be separately evaluableTopics
Vaccines · 1efd24fe Medicine · 1efd24fe
Assessment
Supported
Main unresolved issue: 2 counted evidence items have no independence review; repeats of one origin may be counted as several coverage:0b3df062-5667-8b4f-8b8a-9122bcfadece
Not yet independently audited.Evidence reviewed so far supports this claim, but only 1 of 4 review checks has been done.Every quoted passage was confirmed on the page when Galedra fetched it.
Why?
Strongest counted support: The phase 1 report says antibody responses remained elevated for at least one year after vaccination. weight 2.000000 evidence
Suppressed as dependent: The excerpt directly states responses increased after the boost and remained elevated for at least one year.
Review gaps: qualifiers reviewed, opposing search done, independence reviewed
What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Unresolved.
0.8808 under ledger-default@0.3.0 at snapshot 27745 · state Supported · Review checks: 1 of 4 · stability MEDIUM · 2 sources, 1 independent lineage
How the number was reached
| Link | Working | Weight | Counted as |
|---|---|---|---|
| 1bfdd8c0 support | relevance DIRECT 2.0 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1 | 1.800000 | 0.000000 (dependent strongest only, kept cfdb6137) |
| cfdb6137 support | relevance DIRECT 2.0 × observation MEASUREMENT 1.0 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1 | 2.000000 | 2.000000 |
prior 0.50 → log-odds 0.000000 + 2.000000 (the counted weights) = 2.000000 → probability 0.8808
Your view
Registered views
Nobody has registered a view yet.
Checked as part of
- “A phase 1 trial of the structure-based mRNA-1215 Nipah vaccine in healthy adults reported no serious adverse events and sustained antibody responses through...” · 2 claims · 29 September 2026
Evidence for
-
From A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted
Primary phase 1 immunogenicity follow-up.
-
From A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted
Evidence against
None.
Qualifications
None.
Suppressed as dependent
| Evidence | Group | Kept instead |
|---|---|---|
| 6db3b48a | cfdb6137 |
Inferences
Concluded from
None.
Used as a premise in
None.
Threads
None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.
Claim edges
None. Edges are stored and displayed; v0.1 does not propagate probability across them.
Review checklist
Review checks: 1 of 4
| Check | Done | By |
|---|---|---|
| qualifiers reviewed | no | |
| opposing search done | no | |
| independence reviewed | no | |
| primary source reviewed | yes | 1bfdd8c0, cfdb6137 |
Summary
Supported. The main support is: The phase 1 report says antibody responses remained elevated for at least one year after vaccination. 7b60b3a6
1 further item repeats the same origin and is not independent evidence. 6db3b48a
Review checks: 1 of 4. coverage:0b3df062-5667-8b4f-8b8a-9122bcfadece
Contribution history
| seq | event | detail |
|---|---|---|
| 18299 | APPENDED | |
| 18300 | ACCEPT | AUTOMATIC_AFTER_VALIDATION |
| 18309 | LINK_EVIDENCE | by 1efd24fe (accepted) |
| 24698 | TASK_RESULT | by 1efd24fe (accepted) |
Score trace
{
"claim": "0b3df062-5667-8b4f-8b8a-9122bcfadece",
"links": [
{
"kept": "b7e343ae-ef18-8841-9a9f-6eafcfdb6137",
"link": "2a4c5b74-8e23-8aaa-a7e5-8d511bfdd8c0",
"group": null,
"reason": "dependent_strongest_only",
"edition": "NAMED_OR_UNRELATED",
"evidence": "b05e8dd3-a90a-8ab4-b702-7dae6db3b48a",
"direction": "SUPPORT",
"magnitude": "1.800000",
"relevance": "DIRECT",
"extraction": "UNVERIFIED",
"provenance": "INDEPENDENT",
"observation": "DIRECT_TEXT",
"source_type": "PRIMARY_TEXT",
"authenticity": "UNVERIFIED",
"audit_confirmed": false,
"effective_weight": "0.000000",
"interpretive_steps": 0
},
{
"link": "b7e343ae-ef18-8841-9a9f-6eafcfdb6137",
"group": null,
"edition": "NAMED_OR_UNRELATED",
"evidence": "c871a330-cd54-86f2-9e8d-6c3e7b60b3a6",
"direction": "SUPPORT",
"magnitude": "2.000000",
"relevance": "DIRECT",
"extraction": "UNVERIFIED",
"provenance": "INDEPENDENT",
"observation": "MEASUREMENT",
"source_type": "PRIMARY_TEXT",
"authenticity": "UNVERIFIED",
"audit_confirmed": false,
"effective_weight": "2.000000",
"interpretive_steps": 0
}
],
"model": "ledger-default@0.3.0",
"prior": "0.50",
"variants": {
"spread": "0.1287",
"permissive": "0.9309",
"conservative": "0.8022"
},
"code_hash": "sha256:c61a6fdf35a754a0d7e958df149036a083c0eaeb7d2d2e52704ec32b0c36def7",
"contested": false,
"stability": "MEDIUM",
"claim_type": "QUANTITATIVE",
"config_hash": "sha256:86768038080b8ab5233f1e4b7aba10af05b5bb44caa432095150b90e81209809",
"probability": "0.8808",
"provisional": true,
"evidence_sum": "2.000000",
"snapshot_seq": 25852,
"prior_log_odds": "0.000000",
"support_groups": 1,
"model_dependent": false,
"review_coverage": "0.25",
"truth_evaluable": true,
"assessment_state": "SUPPORTED",
"review_checklist": {
"qualifiers_reviewed": {
"by": [],
"ok": false
},
"opposing_search_done": {
"by": [],
"ok": false
},
"independence_reviewed": {
"by": [],
"ok": false
},
"primary_source_reviewed": {
"by": [
"2a4c5b74-8e23-8aaa-a7e5-8d511bfdd8c0",
"b7e343ae-ef18-8841-9a9f-6eafcfdb6137"
],
"ok": true
}
},
"contradict_groups": 0,
"rounding_boundary": false,
"posterior_log_odds": "2.000000",
"not_applicable_reason": null,
"independence_unreviewed": 2
}